MONTREAL, Feb. 1, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of Natur Produkt International, JSC, a specialty pharmaceutical company in Russia, for approximately $163 million, plus adjustments for net debt and working capital. Natur Produkt has a significant presence in the over-the-counter (OTC) segment in several categories marketed under the umbrella brand, Natur Produkt. Key brands include AntiGrippin, a leading cough and cold remedy, Anti Angin, Sage and Eucaplyptus MA brand names, leading sore throat remedies. About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com. Contact Information: Laurie W. Little 949-461-6002 email@example.com (Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) http://www.valeant.com http://photos.prnewswire.com/prnh/20101025/LA87217LOGO PRN Photo Desk, firstname.lastname@example.org SOURCE: Valeant Pharmaceuticals International, Inc. To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2013/01/c2385.html CO: Valeant Pharmaceuticals International, Inc. NI: HEA MTC MNA -0- Feb/01/2013 13:50 GMT
Valeant Completes Acquisition Of Natur Produkt In Russia
Press spacebar to pause and continue. Press esc to stop.